Muscular Dystrophy - Pipeline Review, H2 2017

  • ID: 4429826
  • Report
  • 139 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • aTyr Pharma Inc
  • Biophytis SAS
  • Fulcrum Therapeutics Inc
  • Marina Biotech Inc
  • Prothelia Inc
  • MORE
Muscular Dystrophy - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Muscular Dystrophy - Pipeline Review, H2 2017, provides an overview of the Muscular Dystrophy (Musculoskeletal Disorders) pipeline landscape.

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Muscular Dystrophy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 2, 1, 27 and 15 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively.

Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acceleron Pharma Inc
  • aTyr Pharma Inc
  • Biophytis SAS
  • Fulcrum Therapeutics Inc
  • Marina Biotech Inc
  • Prothelia Inc
  • MORE
Introduction

Muscular Dystrophy - Overview

Muscular Dystrophy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Muscular Dystrophy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscular Dystrophy - Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Achelios Therapeutics Inc

AMO Pharma Ltd

aTyr Pharma Inc

Benitec Biopharma Ltd

Bio Blast Pharma Ltd

Biophytis SAS

Corcept Therapeutics Inc

Evotec AG

Fulcrum Therapeutics Inc

Genethon SA

Ionis Pharmaceuticals Inc

Marina Biotech Inc

Medestea Research & Production SpA

Novogen Ltd

Pfizer Inc

Prothelia Inc

Recursion Pharmaceuticals Inc

SanBio Inc

Santhera Pharmaceuticals Holding AG

Sarepta Therapeutics Inc

Strykagen Corp

Takeda Pharmaceutical Co Ltd

Ultragenyx Pharmaceutical Inc

WAVE Life Sciences Ltd

Muscular Dystrophy - Drug Profiles

ACE-083 - Drug Profile

Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy - Drug Profile

Antisense RNAi Oligonucleotide to Inhibit DUX4 for Facioscapulohumeral Muscular Dystrophy - Drug Profile

Antisense RNAi Oligonucleotides for Myotonic Dystrophy - Drug Profile

ATYR-1940 - Drug Profile

AVGN-7 - Drug Profile

baliforsen - Drug Profile

BB-301 - Drug Profile

BIO-103 - Drug Profile

domagrozumab - Drug Profile

Fusion Protein to Activate Utrophin for Muscular Dystrophies - Drug Profile

Gene Therapy to Activate Dysferlin for Dysferlinopathies - Drug Profile

Gene Therapy to Activate Dystrophin for Muscular Dystrophy - Drug Profile

IUCT-169 - Drug Profile

IUCT-290 - Drug Profile

IUCT-309 - Drug Profile

ketoprofen - Drug Profile

LR-08 - Drug Profile

mexiletine hydrochloride - Drug Profile

MYO-101 - Drug Profile

MYO-102 - Drug Profile

MYO-103 - Drug Profile

MYO-201 - Drug Profile

MYO-301 - Drug Profile

Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy Type 1 - Drug Profile

Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy Type 1 - Drug Profile

omigapil - Drug Profile

poloxamer - Drug Profile

PRT-01 - Drug Profile

RNAi Gene Therapy to Inhibit Myotilin for LGMD - Drug Profile

RP-33 - Drug Profile

SB-308 - Drug Profile

SIWA-318 - Drug Profile

Small Molecule to Inhibit DUX4 for Muscular Dystrophy - Drug Profile

Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 - Drug Profile

Small Molecule to Target RNA for Myotonic Dystrophy Type 1 - Drug Profile

Small Molecules for Dysferlinopathies - Drug Profile

Small Molecules for Emery-Dreifuss Muscular Dystrophy - Drug Profile

Small Molecules for Facioscapulohumeral Muscular Dystrophy - Drug Profile

Small Molecules for Facioscapulohumeral Muscular Dystrophy - Drug Profile

Small Molecules for Merosin-Deficient Congenital Muscular Dystrophy Type 1A - Drug Profile

Small Molecules for Myotonic Dystrophy - Drug Profile

Small Molecules for Pain - Drug Profile

Small Molecules for Walker-Warburg syndrome - Drug Profile

Small Molecules to Activate SMCHD1 for Facioscapulohumeral Dystrophy - Drug Profile

Small Molecules to Antagonize Glucocorticoid Receptor II for Muscular Dystrophy - Drug Profile

Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I - Drug Profile

Small Molecules to Target RNA for Myotonic Dystrophy - Drug Profile

Stem Cell Therapy for Muscular Dystrophy - Drug Profile

Stem Cell Therapy to Activate ZSCAN4 for Muscular Dystrophy - Drug Profile

Stryka-232 - Drug Profile

Stryka-234 - Drug Profile

Stryka-425 - Drug Profile

Stryka-533 - Drug Profile

Stryka-978 - Drug Profile

tideglusib - Drug Profile

trehalose - Drug Profile

TXA-127 - Drug Profile

VAL-0411 - Drug Profile

WITH-1101 - Drug Profile

XN-001 - Drug Profile

Muscular Dystrophy - Dormant Projects

Muscular Dystrophy - Discontinued Products

Muscular Dystrophy - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Muscular Dystrophy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Muscular Dystrophy - Pipeline by Acceleron Pharma Inc, H2 2017

Muscular Dystrophy - Pipeline by Achelios Therapeutics Inc, H2 2017

Muscular Dystrophy - Pipeline by AMO Pharma Ltd, H2 2017

Muscular Dystrophy - Pipeline by aTyr Pharma Inc, H2 2017

Muscular Dystrophy - Pipeline by Benitec Biopharma Ltd, H2 2017

Muscular Dystrophy - Pipeline by Bio Blast Pharma Ltd, H2 2017

Muscular Dystrophy - Pipeline by Biophytis SAS, H2 2017

Muscular Dystrophy - Pipeline by Corcept Therapeutics Inc, H2 2017

Muscular Dystrophy - Pipeline by Evotec AG, H2 2017

Muscular Dystrophy - Pipeline by Fulcrum Therapeutics Inc, H2 2017

Muscular Dystrophy - Pipeline by Genethon SA, H2 2017

Muscular Dystrophy - Pipeline by Ionis Pharmaceuticals Inc, H2 2017

Muscular Dystrophy - Pipeline by Marina Biotech Inc, H2 2017

Muscular Dystrophy - Pipeline by Medestea Research & Production SpA, H2 2017

Muscular Dystrophy - Pipeline by Novogen Ltd, H2 2017

Muscular Dystrophy - Pipeline by Pfizer Inc, H2 2017

Muscular Dystrophy - Pipeline by Prothelia Inc, H2 2017

Muscular Dystrophy - Pipeline by Recursion Pharmaceuticals Inc, H2 2017

Muscular Dystrophy - Pipeline by SanBio Inc, H2 2017

Muscular Dystrophy - Pipeline by Santhera Pharmaceuticals Holding AG, H2 2017

Muscular Dystrophy - Pipeline by Sarepta Therapeutics Inc, H2 2017

Muscular Dystrophy - Pipeline by Strykagen Corp, H2 2017

Muscular Dystrophy - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Muscular Dystrophy - Pipeline by Ultragenyx Pharmaceutical Inc, H2 2017

Muscular Dystrophy - Pipeline by WAVE Life Sciences Ltd, H2 2017

Muscular Dystrophy - Dormant Projects, H2 2017

Muscular Dystrophy - Dormant Projects, H2 2017 (Contd..1), H2 2017

Muscular Dystrophy - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Muscular Dystrophy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acceleron Pharma Inc
  • Achelios Therapeutics Inc
  • AMO Pharma Ltd
  • aTyr Pharma Inc
  • Benitec Biopharma Ltd
  • Bio Blast Pharma Ltd
  • Biophytis SAS
  • Corcept Therapeutics Inc
  • Evotec AG
  • Fulcrum Therapeutics Inc
  • Genethon SA
  • Ionis Pharmaceuticals Inc
  • Marina Biotech Inc
  • Medestea Research & Production SpA
  • Novogen Ltd
  • Pfizer Inc
  • Prothelia Inc
  • Recursion Pharmaceuticals Inc
  • SanBio Inc
  • Santhera Pharmaceuticals Holding AG
  • Sarepta Therapeutics Inc
  • Strykagen Corp
  • Takeda Pharmaceutical Co Ltd
  • Ultragenyx Pharmaceutical Inc
  • WAVE Life Sciences Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll